Gaetano Aurilio1, Davide Disalvatore2, Giancarlo Pruneri3, Vincenzo Bagnardi4, Giuseppe Viale3, Giuseppe Curigliano5, Laura Adamoli5, Elisabetta Munzone5, Angela Sciandivasci5, Fernando De Vita6, Aron Goldhirsch5, Franco Nolè5. 1. European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy. Electronic address: gaetano.aurilio@ieo.it. 2. European Institute of Oncology, Division of Epidemiology and Biostatistics, via Ripamonti 435, Milan, Italy. 3. European Institute of Oncology, Division of Pathology, via Ripamonti 435, Milan, Italy; University of Milan, School of Medicine, Milan, Italy. 4. European Institute of Oncology, Division of Epidemiology and Biostatistics, via Ripamonti 435, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, via Bicocca degli Arcimboldi 8, 20126 Milan, Italy. 5. European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy. 6. Second University of Naples, Medical Oncology, via Pansini 5, Naples, Italy.
Abstract
BACKGROUND: The discordance in oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) status between primary and recurrent breast cancer is being intensively investigated and a large amount of data have been produced. However, results from different studies are heterogeneous and often conflicting. To highlight this issue, a meta-analysis of published data was performed. METHODS: A literature search was performed using Medline, and all the studies published from 1983 to 2011 comparing changes in ER, PgR and/or HER2 status in patients with matched breast primary and recurrent tumours were included. We used random-effects models to estimate pooled discordance proportions. RESULTS: We selected 48 articles, mostly reporting retrospective studies. Thirty-three, 24 and 31 articles were focused on ER, PgR and HER2 changes, respectively. A total of 4200, 2739 and 2987 tumours were evaluated for ER, PgR and HER2 discordance, respectively. The heterogeneity between study-specific discordance proportions was high for ER (I(2)=91%, p<0.0001), PgR (I(2)=79%, p<0.0001) and HER2 (I(2)=77%, p<0.0001). Pooled discordance proportions were 20% (95% confidence interval (CI): 16-35%) for ER, 33% (95% CI: 29-38%) for PgR and 8% (95% CI: 6-10%) for HER2. Pooled proportions of tumours shifting from positive to negative and from negative to positive were 24% and 14% for ER (p=0.0183), respectively. The same figures were 46% and 15% for PgR (p<0.0001), and 13% and 5% for HER2 (p=0.0004). CONCLUSION: Our findings strengthen the concept that changes in receptor expression may occur during the natural history of breast cancer, suggesting clinical implications and a possible impact on treatment choice.
BACKGROUND: The discordance in oestrogen receptor (ER), progesterone receptor (PgR) and humanepidermal growth factor receptor 2 (HER2) status between primary and recurrent breast cancer is being intensively investigated and a large amount of data have been produced. However, results from different studies are heterogeneous and often conflicting. To highlight this issue, a meta-analysis of published data was performed. METHODS: A literature search was performed using Medline, and all the studies published from 1983 to 2011 comparing changes in ER, PgR and/or HER2 status in patients with matched breast primary and recurrent tumours were included. We used random-effects models to estimate pooled discordance proportions. RESULTS: We selected 48 articles, mostly reporting retrospective studies. Thirty-three, 24 and 31 articles were focused on ER, PgR and HER2 changes, respectively. A total of 4200, 2739 and 2987 tumours were evaluated for ER, PgR and HER2 discordance, respectively. The heterogeneity between study-specific discordance proportions was high for ER (I(2)=91%, p<0.0001), PgR (I(2)=79%, p<0.0001) and HER2 (I(2)=77%, p<0.0001). Pooled discordance proportions were 20% (95% confidence interval (CI): 16-35%) for ER, 33% (95% CI: 29-38%) for PgR and 8% (95% CI: 6-10%) for HER2. Pooled proportions of tumours shifting from positive to negative and from negative to positive were 24% and 14% for ER (p=0.0183), respectively. The same figures were 46% and 15% for PgR (p<0.0001), and 13% and 5% for HER2 (p=0.0004). CONCLUSION: Our findings strengthen the concept that changes in receptor expression may occur during the natural history of breast cancer, suggesting clinical implications and a possible impact on treatment choice.
Authors: Ahmed Basudan; Nolan Priedigkeit; Ryan J Hartmaier; Ethan S Sokol; Amir Bahreini; Rebecca J Watters; Michelle M Boisen; Rohit Bhargava; Kurt R Weiss; Maria M Karsten; Carsten Denkert; Jens-Uwe Blohmer; Jose P Leone; Ronald L Hamilton; Adam M Brufsky; Esther Elishaev; Peter C Lucas; Adrian V Lee; Steffi Oesterreich Journal: Mol Cancer Res Date: 2018-10-24 Impact factor: 5.852
Authors: Guillermo Urrutia; Sergio Laurito; Diego M Marzese; Francisco Gago; Javier Orozco; Olga Tello; Teresita Branham; Emanuel M Campoy; María Roqué Journal: Clin Exp Metastasis Date: 2015-01-28 Impact factor: 5.150
Authors: Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William Sperduto; Emil Lou; Ashlyn Everett; Drexell Hunter Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; James Yu; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: M Banys-Paluchowski; H Schneck; C Blassl; S Schultz; F Meier-Stiegen; D Niederacher; N Krawczyk; E Ruckhaeberle; T Fehm; H Neubauer Journal: Geburtshilfe Frauenheilkd Date: 2015-03 Impact factor: 2.915